Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK (no. 4) Limited

Viiv Healthcare UK Limited

Sirard, Pierre

Levesque, Kathia

Thoraval, Dominique

Timothy P Connolly

B Narasimhulu Naidu

Yasutsugu Ueda

John F Kadow

Kap-Sun Yeung

Michael A Walker

Nicholas A Meanwell

Margaret E Sorenson

Chung-Pin H Chen

Tao Wang

Zhongxing Zhang

Manoj Patel

Kevin M Peese

John D Matiskella

Nachimuthu Soundararajan

Shawn K Pack

David Kenneth Leahy

Pierre Sirard

Kathia Levesque

Dominique Thoraval

David R Langley

Francis Beaulieu

Carl Ouellet

Jacques Banville

Roger Remillard

Serge Plamondon

Mark R Krystal

Paul Michael Scola

Piyasena Hewawasam

Xiaofan Zheng

Stanley V D'Andrea

Zhongyu Wang

Zhizhen Barbara Zheng

Ningning Xu

Juliang Zhu

Chen Li

Li-Qiang Sun

Alicia Regueiro-Ren

Joanne J Bronson

Mark George Saulnier

Richard H Mueller

Thomas W Hudyma

Min Ding

Jason T Goodrich

Eric Mull

Kyle E Parcella

Katharine A Grant-Young

Scott W Martin

Louis Stanley Chupak

Alan Xiangdong Wang

David Bertil Frennesson

Kyle J Eastman

Oak K Kim

Yunhui Zhang

Michael S Bowsher

Yadagiri R Pendri

Zhaoxing Meng

Barry L Johnson

Dane M Springer

Daniel J Tenney

Rongti Li

Laxma Reddy Kolla

Yasutsuga Ueda

Jonathan R Weiss

Dejah T Petsch

Davidb Frennesson

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:

Salts of prodrugs of piperazine and substituted piperidine antiviral agents

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Inhibitors of human immunodeficiency virus replication

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

HIV integrase inhibitors

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:X is C or N with the proviso that when X is N, Rdoes not exist;W is C or N with the proviso that when W is N, Rdoes not exist;V is C;E is hydrogen or a pharmaceutically acceptable salt thereof; andY is selected from the group consisting of  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:L and M are independently selected from the group consisting of C-Calkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Prodrugs of piperazine and substituted piperidine antiviral agents

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed. 

HIV integrase inhibitors: cyclic pyrimidinone compounds

Growing community of inventors

Portland, CT, United States of America

Timothy P Connolly